| Study | Population | Intervention | Comparison | Details of inadequate response/treatment resistance | Comments |
|---|---|---|---|---|---|
|
RCT 16 countries |
N=303 Mean age (years): NR Gender (% female): NR Ethnicity (% BME): NR Baseline severity: NR (more severe) | Olanzapine 6 or 12mg/day + fluoxetine 25 or 50mg/day | Fluoxetine 25 or 50mg/day | TRD: Inadequate response to SSRI after ≥6 weeks at a therapeutic dose at entry into the trial and inadequate response (<30% improvement in MADRS score) to 7 weeks of venlafaxine 75–375mg/day |
Treatment length (weeks): 12 Outcomes:
|
|
RCT US & Canada |
N=288 Mean age (years): 42.1 Gender (% female): 70 Ethnicity (% BME): 9 Baseline severity: MADRS 28.45 (more severe) | Olanzapine 6-12mg/day + fluoxetine 25-50mg/day | Fluoxetine 25-50mg/day | TRD: History of ≥1 failure to respond to SSRI after ≥4 weeks of therapy at a therapeutic dose, and failure to respond (<30% improvement on MADRS) to 7 weeks of nortriptyline 25-175mg/day |
Treatment length (weeks): 8 Outcomes:
|
BME: black and minority ethnic; MADRS: Montgomery-Asberg depression rating scale; NR: not reported; RCT: randomised controlled trial; SSRI: selective serotonin reuptake inhibitor; TRD: treatment-resistant depression
From: Further-line treatment
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.